Interclean Shanghai

Pharma relies on education for patients

80% of the finalists for the ‘Most Valuable Patient Initiative’ Categoryof the 2015 eyeforpharmaPhiladelphia Awards are focussing on education as a means of engaging with and improving the lives of patients.

Projects from Novartis and UCB utilize technology(in particular apps and social media) to engage in real-time with patients, to help them track their symptoms and get immediate answers to questions they have. Judge Simon Davies, of Teen Cancer America commented about the Novartis ‘Me&My COPD’ app; “This is a really well researched and planned project and I particularly liked the effort made to improve interaction and education. The project has great potential to develop for other conditions.” Meanwhile UCB were praised by Judge Dwayne Dixon of Alcon for the “very creative and impactful use of customer/patient knowledge and resources”.

The full list of finalists, announced today, has Novartis, UCB, Bristol-Myers Squibb and Roche all vying for the ultimate accolade in pharma; to be crowned ‘most valuable’ to their patients. The time and resources these companies are investing in order to develop an educated and empowered patient is indicative of the strong industry-wide move towards listening to, and addressing directly, the real needs of the patient.

Internal education was another strong theme. The judging panel was impressed by Bristol-Myers Squibb, GlaxoSmithKline and Leo Pharma’s efforts to advance the internal mindset of the whole corporation towards a patient- or customer- focused way of thinking. According to Dana Evans of Genetech, Chris Preti’s Patient Engagement Team at GSK “seeks to overcome deeply entrenched models of pharmaceutical product marketing focus and is a patient-centric model recognizing the need for behavior change”.

Speaking at the release of the 2015 finalists eyeforpharma Chairman Paul Simms commented; “Educating patients is key to improving health for everyone. I am delighted to see that pharmaceutical companies no longer see the empowered patient as something to be wary of, but something to embrace, and even build their business model around. These finalists are leading the way.”

A comprehensive list of finalists and more detail about their projects can be found online here: www.eyeforpharma.com/philadelphia/awards

Winners will be announced at the eyeforpharma Philadelphia Awards, on Tuesday April 7th 2015 at the Hyatt Regency Philadelphia, Penn’s Landing from 7.30pm, as part of the US’s leading event for commercial pharma roles; eyeforpharma Philadelphia.

For more information contact Awards Manager, Jenna Gottscho on jenna@eyeforpharma.com or visitwww.eyeforpharma.com/philadelphia/awards

 For further queries and enquiries, please contact: 

Jenna Gottscho
Awards Manager
eyeforpharma
jenna@eyeforpharma.com
 

 

Dramatic shifts in pharma drive patient needs to trump all – including C-Suite authority

According to LEO Pharma, Ipsen and Grünenthal  driving patient-centric leadership has become priority as the patient voice shapes the future for the pharmaceutical industry.

Speaking ahead of the eyeforpharma Barcelona 2015 conference, Alberto Grua, CCO at Grünenthal  echoed similar industry commitments to putting patient’s needs to the forefront of their decision making, and stressed Grünenthals personal commitment to leading a patient-centric culture:

“We regard it as our job to better understand the unmet needs of our patients and to provide them with even better products in the future. We want to place the patient at the centre of our efforts. Our goal is to sustainably improve the life situation of patients. That is why we continue to search for possibilities, progress in therapies, collaborations and innovations to reach this goal”.

Alberto Grua will be joined by CEOs Gitte Aabo at Leo Pharma and Marc de Garidel at Ipsen. All three join Barcelona 2015 to demonstrate what patient-centric leadership looks like, and how the industry will evolve based on this emerging paradigm. The event, the largest commercial gathering of pharmaceutical companies in the world, will be attended by all of the key players including UCB, Novartis, Pfizer, Merck, Bayer and Sanofi. The goal? To explore business models which align patient experience with profitability.

Today’s well-informed, well-equipped patient has challenged the industry. To keep ahead of the increasing patient voice, change must start from the top. CEOs are needed to drive innovation and transformation, while continuing to execute current business necessities. The CEO is now responsible for organising a patient-centric leadership which drives the agenda through the entire value chain, ensuring every department can embed new practices and ensure patient needs trump all.

Over 1000 senior pharmaceutical and healthcare executives will join the CEO panel at the summit; which will take place from 24th-26th March, 2015. For more information on the summit, to see who else will be in attendance, or to find out how this year’s agenda will influence your future business practices visit the official website.

For more information contact:

Blair Gottscho
EyeforPharma
(+44) 207-375-7594
blair@eyeforpharma.com

Director General of EFPIA:“Pan-European HTAnecessary”

Richard Bergström, Director General, EFPIA argued passionately in favour of the homogenisation of European HTA bodies and regulation, during a recent interview with Paul Simms, Chairman, eyeforpharma. Asserting that harmonisation would be the only way for market access to make a step improvement, Bergströmexplained that it was in everyone’s interests, not just those of pharmaceutical companies.

All stakeholders need to invest in larger, more wide-ranging data collection and analysis. That includes pharma companies themselves:  “You better make sure you spend wisely, because if you are going to pour in billions into Real World Data systems, they need to deliver. They must be sustainable and sustained over time, because we can't, for each individual, country and product go in and do a bolt-on data capture and then after one year close it down.

“As an industry, we can't have a Slovenian Real World data system; we can't have a separate one for Austria, etc. We need to build a pan-European standardised model and for that to happen you need to have an agreement.”

Bergström believes that pharma companies have nowlargely worked out how to cope with understanding patient need and remodelling their company around that need, albeit admitting there was still a lot more urgent work to be done to see out existing plans.When pushed on where the next frontier lies for pharma executives, Bergström states:“What the industry really needs next is to understand healthcare systems – especially where access is concerned. Pharma hasn’t really figured out how to engage the healthcare system. The skillset needed is a further understanding of healthcare, how it works, who does what, and who makes decisions.  We need to understand how these people budget, how they forecast a budget for a product 2 years from launch. The industry and the payer come from two different worlds, but their conversation needs tomove far beyond price negotiations..”
    
The other fundamental need for collaboration stems from the need to class innovation, and to prepare better national price reimbursement negotiations. The HTAs and payers need to figure out what is valuable to who and, combined with the issues above, this can only become sustainable with a more joined up approach.

“This is coming strongly from the EMA, from the top payers, from the regulators.This is what they want; a new interface.  And therefore the industry needs to also get its act together in figuring out what that interface should look like.”

When asked if he thought this standardisation is inevitable, Bergström agreed that is was and that we need to prepare for it. In June 2015, the industry will be coming together in Amsterdam to engage in hands-on discussions around these issues at eyeforpharma’s Market Access and Pricing Excellence flagship conference . Bergström’s keynote speech as part of an eight-speaker panel – featuring key regulatory and HTA stakeholders from the UK, Spain, Italy, Belgium and the Netherlands – will address this situation in more detail. Ultimately, he asks that this meeting provide “the roadmap for the practical approach the industry needs to move forward on this matter”.

Aidan Brain
VP Market Access
eyeforpharma
abrain@eyeforpharma.com
(+44)0207 375 7513

Janssen Healthcare Innovation two-time finalistsat eyeforpharma Barcelona Awards

Janssen Healthcare Innovation’s Care4Today programme is set to take two of the highest honours at the 2015 eyeforpharma Barcelona Awards as the shortlist was today announced.


Both their Orthopaedic Solutions and Heart Health Solutions initiatives are shortlisted for the ‘Most Valuable Patient’ and ‘Most Valuable HCP’ initiatives, respectively; a testament to the success of the brand’s commitment to transforming healthcare for the consumer.

The names of the shortlisted projects selected from hundreds of initiatives from Europe, Middle East, Africa and Asia/Pac, were released today and have been identified by the judging panel as the front-runners in customerinnovation and value creation in the industry.

Favouring projects which could demonstrate a real improvement in the lives of the consumer, judgeSteve Turley, Lundbeck, commented of the Heart Health Solutions programme: “this is an excellent project based on deep and meaningful insight, making a real difference for the company, HCPs, and patients”. The initiative is a comprehensive cardiac rehabilitation programme which digitises health records allowing for improved referral and recruitment of patients onto cardiac rehabilitation and providing engaging and interactive exercise programmes for patients based on real-time data.

A comprehensive list of finalists can be found online here:
http://www.eyeforpharma.com/barcelona/awards-index.php

Winners will be announced at the2nd annualeyeforpharma Barcelona Awardson Tuesday 24th March at the CCIB, Barcelona from 7.30pm, as part of the largest gathering of pharma executives, eyeforpharma Barcelona. The evening will be attended by the top 200 VIPs from the pharma industry.

For more information contact Awards Manager, Chloe Leighton on
chloe@eyeforpharma.com or visit www.eyeforpharma.com/barcelona/awards

Apps & Digital Resources vie for top honour at eyeforpharma Barcelona Awards

Two thirds of the finalists for the ‘Most Valuable Patient Initiative’ in the 2015 eyeforpharma Barcelona Awards have used interactive digital resources or mobile applications to engage with the patient; a tell-tale sign of the dominance of patient engagement as a focus for pharma right now. The list of finalists, announced today, includes Abbvie, AstraZeneca, Bayer, Janssen Healthcare Innovation and Novartis all vying for the ultimate accolade in pharma; to be crowned ‘most valuable’ to their patients.


Projects from Abbvie, in partnership with communications agency Biosector2 and Janssen Healthcare Innovation, in conjunction with DePuySynthes and the orthopaedic department of Guy’s & St Thomas’ Hospital in London, are based around interactive websites which empower patients to take control of their health and be educated and supported throughout their relevant treatment, while Bayer Healthcare Turkey stands out with their Women’s Health TV, developed by 2014 category winner Pelin Icil, which addresses the issue of poor communication between women and their gynaecologists in Turkey.

The judges, who include patient representatives Heidi Floyd and Jack Whelan as well as senior pharmaceutical executives Alberto Grua, Chief Commercial Officer EU, Australia and North-America and member of the Corporate Executive Board of Grünenthal and John Pugh, Head of Digital Innovation atBoehringerIngelheimfavoured projects which could demonstrate real patient-experience improvement and those which showed a real understanding of culture and patient-need.

Of Janssen Healthcare Innovation’s Care4Today all-encompassing initiative, which combines an interactive patient website and a printed educational pack for hip & knee replacement patient the judges were unanimously impressed. Patient-judge Heidi Floyd commented: “Guiding a patient from beginning to end of their surgical journey, stepping through all the way to end of recovery; magnificent.  As patients, we often are overwhelmed and unable to absorb required data while preparing for life-changing surgery.  This resource appears to be the perfect tool to allow and encourage patients to educate themselves about the intense process at their own pace. Health information such as this will change the future for patients and caregivers worldwide.”

A comprehensive list of finalists can be found online here:
http://www.eyeforpharma.com/barcelona/awards-index.php

Winners will be announced at the2nd annualeyeforpharma Barcelona Awards, on Tuesday 24th March 2015 at the CCIB, Barcelona from 7.30pm, as part of the largest gathering of pharma executives, eyeforpharma Barcelona. The evening will be attended by the top 200 VIPs from the pharma industry.

For more information contact Awards Manager, Chloe Leighton on
chloe@eyeforpharma.com or visit www.eyeforpharma.com/barcelona/awards

Cartagenia launches Bench for Oncology Software Platform dedicated to Variant Assessment Support and

Cartagenia, leader in providing genetics labs and clinicians with software-based workflow support for variant assessment, lab reporting, and integration of diagnostic knowledge-bases, announced today the launch of Bench for Oncology, a new software platform that helps pathology labs conduct variant assessment and reporting tasks in the analysis of tumors.

Bench for Oncology, designed for use in a clinical diagnostic context, is the newest addition to Cartagenia''s suite of Bench products for data management and clinical interpretation support. It allows labs to quickly and efficiently assess gene sequencing information on tumor samples, put the information in context of what is known for that tumor type, and automate lab report drafting.

"The advent of Next Generation Sequencing (NGS) is significantly changing the way pathology labs work," noted Steven Van Vooren, one of Cartagenia''s scientific founders. "Labs need to make sense of considerably more data due to the introduction of NGS, while still maintaining the tight turnaround times required in an oncology setting. Bench for Oncology is designed to help them do that."

Cartagenia has already signed license deals with a number of labs in both Europe and the United States that are now adopting the platform in a diagnostic setting – including the Netherlands Cancer Institute (NKI), a leading European cancer center at the international forefront of cancer research and treatment. Cartagenia worked closely with NKI, and other centers and pathology labs, to be sure the platform fits their various needs.

Among its features, Bench for Oncology allows pathology labs to easily structure their knowledge base of variant, gene, drug, and trial information and keep track of actionable findings. It automates the lab''s variant assessment and reporting pipelines, and removes the need for tedious and time consuming manual lookup and research.

Maartje Vogel, Clinical Laboratory Geneticist at the DNA Diagnostics group of the Pathology Department of NKI, stated: "Automating our variant assessment protocols is essential for us to be able to reach fast turnaround times. With Bench for Oncology, our variant classification pipelines are pre-configured by us in workflows and allow us to very quickly focus on those variants that matter. Combine that with the fact that all relevant knowledge, annotations and databases are integrated into the variant review process, and you get a very powerful reporting pipeline that allows us to create clear and informative lab results for the oncologists – and do this fast."

Cartagenia CEO Herman Verrelst noted that he is excited to be able to roll out the Bench for Oncology platform at the NKI – one of the major cancer centers in Europe. He sees the relationship between Cartagenia and NKI as a growing and dynamic collaborative effort.

"We''re looking forward to our continued collaboration with a prestigious center like NKI, first in its ongoing effort to streamline its diagnostic workflow, but also to integrate our solution into the NKI data warehousing and informatics environment," Verrelst said.

Automation of the lab''s variant assessment and reporting protocols

The close collaboration with pathology labs was key in creating the unique features of Bench for Oncology, Van Vooren added.

"Working closely with the labs it became immediately apparent that there was a critical need for automation. Variant annotation and assessment protocols need to be standardized and automated so time can be spent on true and actionable information," Van Vooren said.

Bench for Oncology brings exactly those tools to the lab, building on a robust platform that provides versioning and audit trails, workflow support, automation of variant assessment and classification protocols, and lab report drafting.

Supporting access to all relevant knowledge sources

"Automation is essential to turnaround times, but it''s only one part of the equation," Van Vooren continued. "Equally important for pathology labs adopting NGS is to have all relevant knowledge at their fingertips – public information on cancer mutations, drugs and trials, as well as the lab''s growing internal knowledge base on actionable variants, previous findings and reports, approved drugs and their likely therapeutic effectiveness in context of molecular makeup, off-label drugs relevant to fully cover a patient''s treatment options, and clinical trials available to the patient."

External knowledge partnerships

Because each tumor is unique, important domain-specific expertise tailored to each individual patient can be essential in reporting personalized and informative diagnosis and treatment options. Some labs have a lot of the required interpretation expertise in house and will benefit from Bench for Oncology''s knowledge management tools to structure the information and automate its use. Other labs prefer to rely on external expert interpretation and curation partners that provide up-to-date and state-of-the-art information on treatment options as a professional service.

For those reasons, Cartagenia Bench Oncology is built around a knowledge integration framework that supports access to several industry-leading knowledge service providers. These knowledge partners specialize in providing personalized, expert-reviewed information for each molecular profile, complementing the automation and lab-specific knowledge integration already offered by Bench Oncology.

"We chose to set up a true framework on which the pathology lab can integrate its own expert knowledge and if desired, work with one or more external service providers that complement the lab''s expertise with patient-specific treatment options," Verrelst added. "In this way, we offer a true end-to-end solution, allowing the lab to have access to information on all treatment options, and create best-of-class reports to the oncologists and referrers."

Cartagenia has set up agreements with a number of leading knowledge providers providing expert curation on actionable variants, drugs and trials, and will announce these partnerships in the near future.

About Cartagenia

Cartagenia supplies diagnostic support software, database systems, and related services to genetic labs and clinicians, enabling them to perform clinically relevant genetic analyses quickly and efficiently, and offer patients and carers high-quality genetic interpretation and counselling.

Cartagenia Bench Lab allows automation of variant assessment protocols and lab report generation for structural and molecular variant assays such as Arrays, Sanger and Next Generation Sequencing. It supports communication with referring physicians, allows labs and clinicians to put variants in their clinical context, and supports confident data sharing.

The Cartagenia Bench platform is built in collaboration with genetics labs and clinical experts involved in routine medical  practice. Because of this, Bench Lab addresses the specific needs of genetic diagnostic labs and clinicians.

Cartagenia Bench is built using a certified ISO13485 Quality Management System and is registered with the FDA as an exempt Class I Medical Device in the United States and as a Class I Medical Device in Europe in conformity with the essential requirements and provisions of the Council Directive 93/42/EEC concerning medical devices, and with the relevant harmonized standards EN ISO62304.

 

 


ICD-10 “Gut Check” and New Opportunities to Bring Case Management Audits and Appeals In-House

ICD-10 implementation and a recent CMS decision create significant compliance, quality, and revenue opportunities for healthcare systems and providers in 2015, according to Michael T. Dougherty, Founder and Chief Executive Officer of Provident Consulting. These accelerate the national trend towards pay for quality and outcomes, he adds.

Dougherty explains the impact of the looming ICD-10 implementation on documentation standards and the nexus to value-based purchasing and quality.
How can healthcare executives be sure they are ready to meet the ICD-10 challenge?

With one year to go, all healthcare CFOs and CEOs should have a good idea of where they stand. That said, now is the time for an honest “gut check”. Critical risk areas are payer readiness, IT system vendor readiness, and clinical documentation training. The first two require tough-minded evaluation of payer and vendor representations, very tight testing plans, and contingency planning in case things go wrong.

Have the payers agreed to test with you?
Are they willing to work through denials on a test basis before go-live? In IT the big wild card is workflow regarding documentation. When will ICD-10 compliant systems be ready? How much time will you have to test the workflows and influence design and customization? We have worked with over 300 IT applications nationally and readiness is still a big concern.

You have talked about executives being ready for October 2, 2015? What do you mean?
Clinical Documentation training for clinicians and CDI Specialists should be well along by now and executives should be asking themselves: How do I support clinicians with documentation tools at the point of care after 10/1/15, especially if I am not satisfied with the workflows in my electronic medical records? Will our training assist with documentation for quality and value-based purchasing in 2015 and beyond? To help our clients deal with this we built DocEdge™ ICD-10. We isolated the most common, most complex, and highest impact documentation and coding challenges, and built clinical flow charts to show documenters, CDI specialists, and coders ICD-10 documentation standards and the concepts they will need for future reimbursement models. DocEdge™ is delivered at the point of care through any mobile device.

In today’s highly regulated healthcare system, what do healthcare organizations overlook that they should not?
There are several areas, but I think the new CMS settlement offer to resolve Patient Status appeals in exchange for a timely partial payment (68 percent of the net payable amount) is an opportunity for high impact cost reduction and quality improvement. Every system needs to analyze this offer on the merits and we are helping several to do this. I think the real opportunity here is to start from a zero baseline of appeals and apply continuous improvement principles and tools to build an effective best practice program. To help clients with this, we built Patient StatusEdge™. It allows hospitals to bring the patient status audit and appeals process in-house with automated workflows facilitating the production of well written, accurate and comprehensive appeals, and key metric reporting for effective program management. It is especially useful for reducing future denials because Appeals Managers can use Patient StatusEdge™ to identify and push continuous improvement training examples to Case Managers, Providers, and Coding staff, while the medical documentation is being reviewed for audits and appeals. This training is tracked to identify high impact areas and to identify individuals requiring more attention.

Any final words of advice?
Adopt a continuous improvement methodology where every time someone touches a clinical record, be it revenue and compliance audits, CDI and Case Management queries and referrals, or Physician Advisor actions, it results in actionable metrics and interventional training delivered as close to the point of care as possible. That approach will reduce errors, improve compliance, and ensure appropriate claims for reimbursement. We do this through our DocEdge™ suite but there are many approaches.

Interview by Sarin Kouyoumdjian-Gurunlian, Press Manager, marcus evans
For more information, please contact Laurel Zevitz at l.zevitz@marcusevansch.com


How Hospitals Can Survive in the New Healthcare Environment

“Over 1,000 hospitals out of the approximately 5,700 across the US will either close or merge with larger hospitals or healthcare systems in the next five to ten years according to some predictions. The reality of the situation is that many hospitals can no longer go it alone. They must look for partners to help bridge the gap between a current reimbursement model that pays on a “per click” basis to one that emphasizes shared savings, shared risk, population health and a trend towards “mega capitation”, advises Tom Gibney, Chief Financial Officer, St. Luke’s Cornwall Hospital / Newburgh.

A speaker at the marcus evans National Healthcare CFO Summit Fall 2014, Gibney believes that regardless of whether or not a hospital falls into a Medicaid expansion state, Healthcare CFOs must quickly determine the reimbursement effect of the expected uptick in insured patients, given the heavy financial burden borne by patients in the health exchange plans, primarily those in the bronze and silver buckets.

For example, in New York, approximately one million individuals signed up for insurance under Obamacare; 650,000 qualified for Medicaid with the remaining 350,000 signing up for one of the four health exchange plans, with the majority of those folks choosing the less expensive, but higher out-of-pocket cost, bronze and silver plans. “Collecting from this patient population could be a significant challenge for hospitals going forward. It is a significant unknown but too early in the process to identify what burden it will place on us,” Gibney explains.

“CFOs have to approach this new reality with their eyes wide open. On the surface, a patient who presents an insurance card (who never did before) is a good thing. But the positive feeling that comes from that experience can quickly evaporate if in the end, the visit or procedure is not fully paid for.”

So far in 2014, St. Luke’s Cornwall Hospital has seen its Medicaid population increase while its self-pay population has gone down. “In a vacuum, that is a good thing. All other things being equal, this provides us with more direct reimbursement for those patients compared to last year. The flip side of the equation is that a lot of work may be involved in collecting the ultimate amount we are due.”

He concludes: “To survive financially, hospitals may need to proactively seek out partners. Most hospitals have extracted as much as they can out of the cost side of the equation. The next step is to play to a bigger patient audience, take-on-risk, share savings, and reap the benefits of economies of scale. The only way to achieve those goals is to partner with other hospitals or healthcare systems. When a State as big as New York announces a stated goal of reducing avoidable hospitalizations and ER visits by 25 percent over the next five to ten years, is there any other choice?”

Interview by Sarin Kouyoumdjian-Gurunlian, Press Manager, marcus evans

For more information, please contact Laurel Zevitz at l.zevitz@marcusevansch.com

Philips and Dutch Radboud university medical center debut wearable diagnostic prototype for chronic

At the Dreamforce 2014 conference in San Francisco, Royal Philips (NYSE: PHG; AEX: PHIA) and Nijmegen, the Netherlands-based Radboud university medical center (Radboudumc) announced the debut of a prototype to support patients with chronic obstructive pulmonary disease (COPD). The launch marks the start of joint explorations between Philips and Radboudumc to apply mobile, digital and cloud technologies to improve patient outcomes, care coordination and patient empowerment across the health continuum.

According to the US Centers for Disease Control and Prevention (CDC), 117 million Americans, or nearly one-half of the US adult population, have at least one chronic condition, and one in four adults has two or more.  The CDC estimates that caring for patients with chronic conditions accounts for 70% of the annual health care spend in the U.S.  In a study released by The World Economic Forum, the global economic impact of the five leading non-communicable diseases – cardiovascular disease, chronic respiratory disease, cancer, diabetes and mental ill-health – could total USD 47 trillion over the next 20 years.

Management of COPD is challenging and often costly, as the progressive nature of the disease leads many patients to require complicated therapies and frequent hospital readmissions. At the same time, consumers are increasingly looking for new ways to take control of their personal health in order to live healthier and better lives.

“Unlike other wearable solutions recently introduced to the market, this prototype collects more than just wellness data from otherwise healthy people,” said Jeroen Tas, CEO Healthcare Informatics Solutions and Services at Philips. “We are demonstrating the power of harnessing both clinical and personal health information to better manage chronic disease patients across the health continuum, from healthy living, prevention, diagnosis, treatment, recovery and home care.”

How it works
The wearable diagnostic prototype for COPD patients feeds data collected from patients at home to clinicians through the Philips HealthSuite Digital Platform to two clinical applications currently available on the cloud-based platform – eCareCompanion and eCareCoordinator – which both recently received FDA 510(k) clearance. Once a COPD patient has left the hospital, a wearable diagnostic prototype collects data day and night – including physical activity/inactivity, respiratory indicator, heart rhythm and heart rate variability. That data is then sent via the cloud to the Philips HealthSuite Digital Platform, where it is shared with the appropriate care providers via the eCareCoordinator application, presenting a more complete view of the patient’s illness.

“Together with Philips, we are exploring and developing tools to enable patients to be true partners in their own health care, including Hereismydata™ and thus creating a digital platform for patients to collect data from EMRs as well as personal wearable technology,” said Lucien Engelen, director REshape Innovation Center at Radboud university medical center. “Our collaboration with Philips creates the scale needed for a globalizing sustainable healthcare approach.”

Radboudumc is considered to be one of the most innovative medical centers in Europe focused on digital solutions to enable patient centric care. The innovation center at Radboudumc, part of the network of Singularity University’s Exponential Medicine track in Silicon Valley, is at the forefront of the convergence of technology and patient empowerment, both inside and outside the hospital.

As part of Philips vision for the HealthSuite Digital Platform, the company is working to create a suite of open application programming interfaces (APIs) that can be used by developers to create innovative applications for hospitals and health systems. Visitors to the Philips booth in the Salesforce Customer Showcase at Dreamforce can sign up to learn more about this Developers Toolkit, expected to be available in early 2015.

Members of the press and conference attendees can learn more about the Philips-Radboudumc  innovative COPD prototype at the Dreamforce 2014 conference in San Francisco from October 13-16: Demos will be shown at the Dreamforce Industry Health and Life Sciences Showcase (Moscone South/Gateway) and the Customer Showcase areas (Moscone West).

For updates on further platform developments, visit www.philips.com/dreamforce and follow the #DF14  conversation at @PhilipsHealth.

Salesforce and others are trademarks of salesforce.com , inc.

For further information, please contact:

Rachel Bloom-Baglin
Philips Healthcare
Tel: +1 978 7609007
E-mail: Rachel.Bloom-Baglin@philips.com

Steve Klink
Philips Group Communications
Tel: +31 6 10888824
E-mail: steve.klink@philips.com

Viola Peulen
Radboud university medical center
Tel: +31 6 55346484
E-mail: Viola.peulen@radboudumc.nl

About Royal Philips:
Royal Philips (NYSE: PHG, AEX: PHIA) is a diversified health and well-being company, focused on improving people’s lives through meaningful innovation in the areas of Healthcare, Consumer Lifestyle and Lighting. Headquartered in the Netherlands, Philips posted 2013 sales of EUR 23.3 billion and employs approximately 112,000 employees with sales and services in more than 100 countries. The company is a leader in cardiac care, acute care and home healthcare, energy efficient lighting solutions and new lighting applications, as well as male shaving and grooming and oral healthcare. News from Philips is located at www.philips.com/newscenter.

About Radboud university medical center
Radboud university medical center is an institute for patient care, research and education & training, located in Nijmegen, the Netherlands. Our mission is to have a significant impact on healthcare. We aim to be a frontrunner in the development of innovative, sustainable and affordable healthcare. By offering excellent quality, participatory and personalized healthcare, operational excellence and sustainable networks. Our almost 10,000 employees and over 3,000 students do their utmost every day to make a positive contribution to the future of healthcare and medical sciences.

Translate »